OClawVPS.com
EVerZom
Edit

EVerZom

http://www.everzom.com/
Last activity: 14.10.2025
Active
Categories: BioTechExosomesHealthcareRegenerativeMedicineTherapeutics
EverZom is a nanomedecine biotech companies developing a GMP compliant extracellular vesicle manufacturing platform based on a unique proprietary technology for pharmaceutical researchers developing breakthrough biotherapies. Extracellular vesicles which encompass exosomes, microvesicles and apoptotic bodies are the tools used by cells to communicate with each others. Extracellular vesicles have reparative and regenerative properties and are seen as an alternative to cell therapies for tissue regeneration. They eliminate many of the risks associated with cell therapies and carry significant benefits that the medical world considers to be game changing. There is a major challenge in the production of extracellular vesicles at commercial scale which is holding back the development of new therapies. EVerZom aims at overcoming this challenge with its breakthrough patented production method. This technology was developped in collaboration with the Laboratory Matières et Systèmes Complexes from the University of Paris and the CNRS. As an exosome CRO, we provide exosome characterization services, exosome quality control and analytics services, isolation, purification services, process development and manufacturing services.
Followers
3.18K
Mentions
5
Location: France
Employees: 11-50
Total raised: $15.82M
Founded date: 2019

Investors 1

DateNameWebsite
14.10.2025Capital Gr...capitalgra...

Funding Rounds 3

DateSeriesAmountInvestors
14.10.2025-$11.69MCapital Gr...
17.11.2021Grant$2.8M-
01.12.2020-$1.33M-

Mentions in press and media 5

DateTitleDescription
14.10.2025EVerZom Raises €10M in FundingEVerZom, a Strasbourg, France-based biotechnology company developing exosome-based therapies for regenerative medicine applications, raised €10M in funding. The round was led by Capital Grand Est, the European Innovation Council (EIC) Fund,...
05.03.2024Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.-
01.12.2020EVerZom Raises €1.1M in FundingEVerZom, a Paris, France-based biopharmaceutical company specialized in the bioproduction of exosomes, raised €1.1m in funding. Backers included institutional and private investors. This funding will speed up the platform development and sc...
-Women and entrepreneurs: inspiring storiesParis&Co's female entrepreneurs have got talent! Since 2019, 1/3 of the Paris&Co startup management teams have been 100% female or mixed. This encouraging progression confirms the need to continue our efforts to increase business cr...
-EVerZom“EVerZom is an exosome biotech company developing exosome therapeutics in digestive tissue healing, fistula and organ regeneration.”

Reviews 0

Sign up to leave a review

Sign up Log In